Quarterly report pursuant to Section 13 or 15(d)

Subsequent Event (Details)

v2.4.0.8
Subsequent Event (Details) (USD $)
9 Months Ended 0 Months Ended 0 Months Ended 0 Months Ended
Sep. 30, 2014
Dec. 31, 2013
Sep. 30, 2014
Diagnostic Test - Pancreas [Member]
Oct. 31, 2014
Subsequent Event [Member]
Oct. 31, 2014
Subsequent Event [Member]
Term Loan [Member]
Oct. 31, 2014
Subsequent Event [Member]
Term Loan [Member]
Oct. 31, 2014
Subsequent Event [Member]
Term Loan [Member]
Prior to October 31, 2016
Oct. 31, 2014
Subsequent Event [Member]
Term Loan [Member]
After October 31, 2016, prior to October 31, 2017
Oct. 31, 2014
Subsequent Event [Member]
Term Loan [Member]
After October 31, 2017, prior to October 31, 2018
Oct. 31, 2014
Subsequent Event [Member]
Term Loan [Member]
London Interbank Offered Rate (LIBOR) [Member]
Oct. 31, 2014
Subsequent Event [Member]
RedPath [Member]
installment
Oct. 31, 2014
Subsequent Event [Member]
RedPath [Member]
Common Stock, Milestone One [Member]
Oct. 31, 2014
Subsequent Event [Member]
RedPath [Member]
Common Stock, Milestone Two [Member]
Oct. 31, 2014
Subsequent Event [Member]
RedPath [Member]
Cash Payments, Milestone One [Member]
Oct. 31, 2014
Subsequent Event [Member]
RedPath [Member]
Cash Payments, Milestone One [Member]
Barrett's Esophagus Management [Member]
Oct. 31, 2014
Subsequent Event [Member]
RedPath [Member]
Cash Payments, Milestone Two [Member]
Oct. 31, 2014
Subsequent Event [Member]
RedPath [Member]
Cash Payments, Milestone Two [Member]
Basket of Assays [Member]
Oct. 31, 2014
Subsequent Event [Member]
RedPath [Member]
Revenue Based Payments, A [Member]
Oct. 31, 2014
Subsequent Event [Member]
RedPath [Member]
Revenue Based Payments, A [Member]
Diagnostic Test - Pancreas [Member]
Oct. 31, 2014
Subsequent Event [Member]
RedPath [Member]
Revenue Based Payments, B [Member]
Minimum [Member]
Oct. 31, 2014
Subsequent Event [Member]
RedPath [Member]
Revenue Based Payments, B [Member]
Maximum [Member]
Oct. 31, 2014
Subsequent Event [Member]
RedPath [Member]
Revenue Based Payments, B [Member]
Barrett's Esophagus Management [Member]
Subsequent Event [Line Items]                                            
Cash payment                     $ 12,000,000                      
Notes issued                     11,000,000                      
Number of payment installments                     8                      
Interest rate in event of default                     5.00%                      
Number of shares issuable                       500,000 500,000                  
Common stock, par value $ 0.01 $ 0.01                                        
Contingent cash payment                           5,000,000   5,000,000            
Annual net sales, basis for contingent cash payments                             14,000,000   37,000,000          
Royalty percentage     5.00%                             6.50%   10.00% 20.00%  
Annual net sales, minimum basis for royalty payments                                     12,000,000     30,000,000
Annual net sales, maximum basis for royalty payments                                           30,000,000
Loan amount           20,000,000                                
Variable rate basis                   three month LIBOR                        
Floor of interest rate basis         1.00%                                  
Spread on variable rate                   12.50%                        
Increase in interest in case of default         3.00%                                  
Quarterly maximum, revenue payment         250,000                                  
Revenue payment, percentage         125.00%                                  
Origination fee           300,000                                
Exit fee         800,000                                  
Prepayment fee, percentage of loan             6.00% 5.00% 2.00%                          
Prepayment fee, percentage of revenue         1.30%                                  
Prepayment fee, base for revenue percentage         80,000,000                                  
Net proceeds received from Credit Agreement       $ 19,600,000